Skip to content

Effect of Daruharidra churna and Arogyavardhini vati in Medoroga - abnormal fat level in body

A randomized controlled clinical trial to study the effect of Ayurvedic management with Daruharidra churna and Aarogyavardhini vati on Medoroga with special reference to Dyslipidemia - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085306
Enrollment
70
Registered
2025-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Sponsors

Dr Roshan Rushikesh Patil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.The patient having age between 18 years to 60 years and irrespective of socioeconomic status, sex and religion. 2. Newly diagnosed Dyslipidemic patients 3. Patient associated with hypertension 4. Patient having Serum Total Cholesterol Level more than or equal to 200mg/dl 5. Patient having Serum Triglyceride Level more than or equal to 150mg/dl 6. Patient having LDL Cholesterol more than or equal to 100 mg/dl 7. Patient having HDL Cholesterol less than or equal to 40 mg/dl .

Exclusion criteria

Exclusion criteria: 1. The patient having Cardiovascular disease, pulmonary, renal and hepatic disease etc. 2. pregnant women 3. DYSLIPIDEMIA due to drugs e.g. Anticonvulsant, Beta blockers,Corticosteroid etc 4. Patient having history of metabolic disorders and Endocrine diseases such as Diabetes mellitus ,etc

Design outcomes

Primary

MeasureTime frame
Reduction in signs and symptoms of Medoroga after ingestion of Daruharidra churna and Aarogyavardhini vatiTimepoint: 7 weeks

Secondary

MeasureTime frame
Where the trial group stands in comparison with control groupTimepoint: 18 Months

Countries

India

Contacts

Public ContactDr Roshan Rushikesh Patil

SMBT Ayurved college and Hospital

hiramanwarungase@yahoo.com9420364157

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026